MEXICO CITY, April 24, 2024 /PRNewswire/ -- Genomma Lab Internacional, S.A.B. de C.V. (BMV:LAB) ("Genomma" or "the Company"), today announced its results for the first quarter of 2024. All figures included herein are stated in nominal Mexican pesos and have been prepared in accordance with International Financial Reporting Standards (IFRS), unless otherwise mentioned. Comments from our CEO, Marco Sparvieri "Our EBITDA margin expanded significantly, reaching 22.3% in Q1 2024, an increase above 150 basis points year on year, driven by cost efficiencies through our manufacturing plant and the focus on our productivity initiatives. Our productivity goals remain on track, with a 40% progress to date towards Ps. $1,800 MM in annual cost savings by 2027." Q1 2024 Financial Summary The following table provides a summary of the Company's Income Statement, in millions of Mexican pesos. Q1 2024 % sales Q1 2023 % sales var % Like-for-like Sales(1) 9.7 % Net Sales (ex Argentina) 3,675.3 3,473.7 5.8 % Net Sales 4,197.3 100.0 % 4,178.2 100.0 % 0.5 %